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ABSTRACT 
        
     A serological survey was carried out to estimate the magnitude and the 
prevalence of avian influenza (AI) antibodies in Khartoum state 
population.  
  A total of 222 serum samples were collected from individuals, without 
any apparent clinical signs of influenza or influenza like diseases, while 
attending the Sudanese Atomic Energy Commission laboratories in 
Khartoum and Omdurman. The collected sera were containing 179 
female samples and 43 male samples. The collected sera were first tested 
by AGID test, the results showed that 76 samples out of 222 (34.2%) 
were positive for influenza A type. 
        Screening of the positive sera by hemagglutination inhibition (HI) 
test for sub-typing antibodies, using H5N1 and H7N3 as antigens and 
pretreatment of sera to remove nonspecific inhibitors, revealed that 13 out 
of 76 were positive for H5 antibodies and only 5 samples were positive 
against H7.From the positive samples to H5 there were 8 samples from 
Khartoum and 5 from Omdurman area, and the 5 positive sera to H7 
contain 3 samples from Khartoum and the rest 2 were from Omdurman.   
But due to the inability of HI test to detect low titers of antibodies to 
avian influenza viruses (AIV) in human sera, these results may be under- 
estimated. 
        The finding of this survey is that, there are circulating H5 and H7 
viruses among Khartoum state environment, but without further 
investigation we can not prove are they H5N1 and H7N3 or not.   
 
 
 
  ﻣﻠﺨﺺ ﺍﻷﻃﺮﻭﺣﺔ
  
 ﻟﺒﻌﺾ ﻀﺎﺩﺓﺍﳌﺟﺴﺎﻡ  ﺍﻷﻣﻘﺪﺍِﺭ ﻭﺇﻧﺘﺸﺎِﺭ ﻣﺼﻠﻰ ﻟﺘﺤﺪﻳﺪ ﻣﺴﺢﰱ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﰎ ﺍﺟﺮﺍﺀ       
 ﺑﺎﺳﺘﺨﺪﺍﻡ ﺍﺧﺘﺒﺎﺭﻯ ﺍﻻﻧﺘﺸﺎﺭ ﺍﳌﻨﺎﻋﻰ ﺍﳋﺮﻃﻮﻡﻭﻻﻳﺔ  ﺳﻜﺎِﻥ  ﺟﺰﺀ ﻣﻦﰲ ِﺭﻮ ﺍﻧﻔﻠﻮﻧﺰﺍ ﺍﻟﻄﻴﻓﲑﻭﺳﺎﺕ
  .ﰱ ﺍﳉﻞ ﻟﺘﺤﺪﻳﺪ ﺍﻟﻨﻤﻂ ﺍﳌﺼﻠﻰ ﻭ ﺗﺜﺒﻴﻂ ﺍﻟﺘﻼﺯﻥ ﻟﺘﺤﺪﻳﺪ ﻧﻮﻉ ﺍﻟﺴﻼﻟﺔ 
 ﻺﻧﻔﻠﻮﻧﺰﺍ ﺃﹶﻭ ﻟ، ﺑﺪﻭﻥ ﺃﻱ ﺇﺷﺎﺭﺍﺕ ﺳﺮﻳﺮﻳﺔ ﻇﺎﻫﺮﺓ ﺃﺷﺨﺎﺹ ﻋﻴﻨﺔ ﻣﺼِﻞ ِﻣﻦ222 ﻊﰎ ﲨ
ﺨﺘﱪﺍﺕ ﳉﻨِﺔ ﺍﻟﻄﺎﻗِﺔ ﺍﻟﺬﺭﻳِﺔ ﺍﻟﺴﻮﺩﺍﻧﻴِﺔ ﰲ ﺍﳋﺮﻃﻮﻡ ﳌ ﺃﺛﻨﺎﺀ ﺯﻳﺎﺭﻢ ُﻧﻔﻠﻮﻧﺰﺍ  ﺍﻹﻣﺜﻞ ﳍﺎ ﺃﻋﺮﺍﺽ ﺃﻣﺮﺍِﺽ
 ﺍﻟﺒﺪﺀ ﰱ .ﺭﻮﺫﻛ  ﻋﻴﻨﺔﹶ34 ﻭﺍﻧﺎﺙﹶ ﻋﻴﻨﺔﹶ 971 ﺍﻟﻌﻴﻨﺎﺕ ﺍﻟﱴ ﲨﻌﺖ ﻛﺎﻧﺖ ﲢﺘﻮﻯ ﻋﻠﻰ  .ﺃﻡ ﺩﺭﻣﺎﻥﻭ
ﲨﻠﺔ  ﻣﻦ ﻋﻴﻨﺔﹶ 67 ﺑﺄﻥﹼ ﺃﻭﺿﺤﺖ ﺍﻟﻨﺘﺎﺋﺞ، ﺍﻷﻧﺘﺸﺎﺭ ﺍﳌﻨﺎﻋﻰ ﰱ ﻫﻼﻡ ﺍﳉِﻞﺑﺈﺧﺘﺒﺎﺭﰎ ﻓﺤﺺ ﺍﻟﻌﻴﻨﺎﺕ 
  .   A ﻣﻦ ﺍﻟﻨﻤﻂ ﻛﹶﺎﻧﺖ ﺇﳚﺎﺑﻴﺔ ﻟﻺﻧﻔﻠﻮﻧﺰﺍ %(2.43) ﺍﻟﻌﻴﻨﺎﺕ
 ﺈﺳﺘﻌﻤﺎﻝﺗﺜﺒﻴﻂ ﺍﻟﺘﻼﺯﻥ ﻟﺘﺤﺪﻳﺪ ﺍﻟﺴﻼﻟﺔ ﺑﺈﺧﺘﺒﺎﺭ ﺑA ﺍﻟﻌﻴﻨﺎﺕ ﺍﳌﻮﺟﺒﺔ ﻟﻠﻨﻤﻂ  ﻓﺤﺺﻋﻨﺪ 
ﻣﺜﺒﻄﺎﺕ ﺍﻟﺘﻼﺯﻥ ،ﻹﺯﺍﻟﺔ  ﺍﻟﺴﲑﻡ ﻗﺒﻞ ﺍﻷﺧﺘﺒﺎﺭ ﻭ ﻣﻌﺎﳉﺔﻨﺎﺕ ﻛﺄﻧﺘﺠﻴ 3 N 7 H ﻭ 1 N 5 H
 5ﻭ  5 H  ﻝﻀﺎﺩِﺓ ﺍﳌﺟﺴﺎﻡﻸ ﻛﹶﺎﻧﺖ ﺇﳚﺎﺑﻴﺔ ﻟ67  ﻋﻴﻨﺔ ﻣﻦ ﳎﻤﻮﻉ31 ﺑﺄﻥﹼ ﻭﺟﺪ، ﻏﲑ ﺍﻟﻨﻮﻋﻴﺔ
 ﻋﻴﻨﺎِﺕ ِﻣﻦ 8ﻛﺎﻥ ﻫﻨﺎﻙ  5 H ِﻣﻦ ﺍﻟﻌﻴﻨﺎِﺕ ﺍﻹﳚﺎﺑﻴِﺔ ﻝ  7 H .ﺪ ﻛﹶﺎﻧﺖ ﺇﳚﺎﺑﻴﺔ ﺿ ﻓﻘﻂﻋﻴﻨﺎِﺕ
 3ﻛﺎﻧﺖ ﻫﻨﺎﻟﻚ  7 H ﻟﻞ  ﻌﻴﻨﺎﺕ ﺍﳋﻤﺲ ﺍﳌﻮﺟﺒﺔﺍﻟـﻣﻦ ، ﻭﻣﺎﻥﺃﻣﺪﺭ  ِﻣﻦ ﻣﻨﻄﻘِﺔ5ﺍﳋﺮﻃﻮﻡ ﻭ
  .    ﺃﻡ ﺩﺭﻣﺎﻥ ِﻣﻦﺖﻋﻴﻨﺎِﺕ ِﻣﻦ ﺍﳋﺮﻃﻮﻡ ﻭﺍﻟﺒﻘﻴﺔ  ﻛﹶﺎﻧ
ﻣﻨﺨﻔﻀﺔ ِﻣﻦ ﺍﻷﺟﺴﺎﻡ  ﻣﻌﺎﻳﲑ  ﻹﻛِﺘﺸﺎﻑﺍﺧﺘﺒﺎﺭﺗﺜﺒﻴﻂ ﺍﻟﺘﻼﺯﻥﹰﻟﻜﻦ ﺑﺴﺒﺐ ﻋﺪِﻡ ﻗﺎﺑﻠﻴﺔ 
ﺃﻋﻠﻰ ﳑﺎ  ﻗﹶﺪ ﺗﻜﹸﻮﻥ ، ﻫﺬﻩ ﺍﻟﻨﺘﺎِﺋِﺞ  ﺍﻹﻧﺴﺎِﻥ ﻣﺼﻞﰲ )VIA( ﺭﻮﻔﲑﻭﺳﺎِﺕ ﺇﻧﻔﻠﻮﻧﺰﺍ ﺍﻟﻄﻴﻟﺍﳌﻀﺎﺩِﺓ  
  .ﰎ ﺍﳊﺼﻮﻝ ﻋﻠﻴﻪ
  ﺑﻴﺌِﺔﰱِ  7 Hﻭ 5 H  ﻭﺟﻮﺩ ﻟﻠﻔﲑﻭﺳﺎﺕ ﻣﻦ ﺍﻟﻨﻮﻋﲔﻚﻟ ﺃﻥﹼ ﻫﻨﺎﺧﻠﺼﺖ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺍﱃ
ﺍﺛﺒﺎﺕ ﻣﺎ ﺍﺫﺍ ﻛﺎﻧﺖ ﻫﺬﻩ  ﻟﻴﺲ ﺑﺎﻹﻣﻜﺎﻥ ﻓﺎﻧﻪ  ِﻯ ﺁﺧﺮﺍﺧﺘﺒﺎﺭﺍﺕ ، ﻟﻜﻦ ﺑﺪﻭﻥ  ﺍﳋﺮﻃﻮﻡﻭﻻﻳﺔ
  .ﻡ ﻻﺃﹶ 3 N 7 H ﻭ 1 N 5 H  ﺍﻟﻔﲑﻭﺳﺎﺕ ﻫﻰ
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
       Influenza A virus genus is a member of the family Orthomyxoviridae 
(Lamb, 1989) which include also the genera: Influenza B, Influenza C 
and Thogoto viruses. The genome of influenza A virus is composed of 8 
RNA segments, two of these molecules are most important in 
classification of influenza viruses, and they are; HA segment which 
incodes the haemagglutinin protein, and the NA segment which incodes 
the neuraminidase protein. (Murphy, Gibbs, Horzinek, and Studdert. 
1999).   
      Influenza viruses spread from person to person via small particle 
aerosols and then invade the cells of the upper respiratory system, bind to 
carbohydrates on the glycoprotein of the host epithelial cells and enter by 
receptor mediated endocytosis (Lamb, 1989). Since the survey done by 
Salim (1970) which proved the presence of (H3N2) A2 1/68/Hong Kong 
subtype in Sudan, there were no further researches in this subject. Also 
due to the last avian influenza outbreak, and the acute cases symptoms, 
which appear to be an influenza disease, there was a need to determine 
the level of influenza viruses' antibodies in Sudanese population sera.  
In the reports of many authors, there is considerable variation in data for 
comparative studies upon diagnostic tests for detection of respective 
antibodies in spontaneous (Edair, Todd, McKillop And McNulty. 1989; 
Edair, Burns, McNulty and Todd. 1990; Arenas, Carranza, Perea, 
Miranda, Maldonado and Hermoso. 1990; Boer, Back and Osterhaus. 
1990; Lamichhane and Kirkegaard. 1997; Zhou, Chan, Heckert, Riva and 
Cantin. 1998; Sala, Cordioli, Moreno-Martin, Tolles, Brocchi, Piccirillo 
and Lavazza. 2003;  Meilin, Wang, Zhang, Zhao, Li, Tan and Chen. 
2004), and experimental (Maulemans, Carlier, Gonze and Petit. 1987; 
Beck and Swayne. 1997) infections. In some cases, higher positive results 
have been obtained in sera tested by means of hemagglutination 
inhibition (HI) test compared to either immunodiffusion test (IDT) or 
Enzyme linked immunosorbbent assay (ELISA) (Zhou et al., 1998; Sala 
et al., 2003). 
Serological diagnosis is important when clinical specimens are not 
available or when the laboratory does not have the resources of virus 
isolation. Serological methods such as hemagglutination inhibition (HI), 
virus neutralization (VN) and ELISA are useful in epidemiological, 
immunological studies as well as in the evaluation of vaccine 
immunogenicity (WHO Manual, 2002).  
The hemagglutination inhibition (HI) test, which detects subtype-specific 
antibodies against hemagglutinin (HA), is commonly used for serologic 
diagnosis of influenza virus infection and for determination of 
susceptibility to influenza virus in epidemiologic and vaccine studies.  
 Naturally occurring inhibitors of hemagglutination by influenza viruses 
present in the sera of humans and animals were first described by Francis 
(1947). These substances act like antibody in an HAI test by interacting 
with the influenza HA and thus preventing agglutination of erythrocytes 
(RBCs) by the virus. Three known classes of inhibitors, designated alpha, 
beta, and gamma, have been detected in human sera (Krizanova and 
Rathova. 1969). 
    Hemagglutination inhibition test was used to detect antibodies to H7 
infection in human sera that collected from persons exposed to poultry 
and showed subclinical infection which revealed positive of 49% of 508 
and in 64% of 63 persons exposed to A (H7) infected persons (Meijer, A., 
Bosman, A., van de Kamp, E.H.M., Wilbrink, B., Holle, M. D. B. and 
Koopmans, M. 2006). Also HI test detected H5-specific antibody in 
single serum samples from two of three patients with culture-confirmed 
H5N1 virus infections (Rowe, Abernathy, Jean Hu-Primmer, Thompson, 
Lu, Lim, Fukuda, Cox and Katz. 1999). 
 
 
 
 
 
  Objectives: 
-General Objectives: 
Serosurvillance for avian influenza A virus among human in Khartoum 
state population. 
-Specific Objectives: 
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Chapter One 
LITRATURE REVIEW 
 1.1 Definition of influenza disease: 
       Influenza is an acute respiratory disease caused by the influenza 
virus and can spread rapidly and widely in the winter season. About 
20% of children and 5% of adults world-wide develop symptomatic 
influenza each year (Yohannes, Roche, Spencer and Hampson. 2003). 
It causes a broad range of illness, from asymptomatic infection through 
various respiratory syndromes, to fulminate primary viral and 
secondary bacterial pneumonia. Epidemics and pandemics of influenza 
have been documented for centuries, with the first clear record dated 
back in 1580 (Potter. 2001). 
    Avian influenza (AI) is a highly contagious disease caused by type 
A influenza viruses that are members of the family Orthomyxoviridae 
in the genus Influenza A virus (OIE, 2005). Infection with low-
pathogenic avian influenza viruses (LPAIV) usually is asymptomatic 
or it induces mild respiratory symptoms, but it can rapidly reduce egg 
production in poultry. Infection with highly pathogenic avian influenza 
viruses (HPAIV) is characterized by the sudden onset of fatal systemic 
disease in susceptible species. Importantly, some strains of LPAIV can 
serve as progenitors that rapidly mutate into HPAIV, which may infect 
humans, causing death, as evidenced by the recent outbreaks in Asia 
(Fisher, 2006). 
            Influenza viruses are important pathogens of animals, but only 
rarely are zoonotic. Instead, they are the ultimate species jumpers, for 
ever evolving host range variants in animals that become epidemic and 
even pandemic when they invade humans. Therefore, veterinary and 
human concerns over influenza are tightly linked. (Murphy et al., 
1999). 
1.2       History of the disease: 
1.2.1   History of the disease in the world: 
      Influenza has probably existed from antiquity, although the lack of 
specific pathognomonic signs makes this assertion less definite than in 
the case of smallpox or cholera (Kilbourne, 1987). Even so, historical 
records of rapidly spreading of catarrhal fevers, in Great Britain, suggest 
that major influenza epidemics affected human populations as early as the 
sixteenth century. In spite the lacking of direct evidence for horse-to-
human transmission of influenza viruses, the sizeable concentrations of 
these animals near previous centers of human population makes them 
attractive candidates as disease intermediaries (Hirsch, 1883). In modern 
times, pigs have been accorded a prominent role in the generation of 
major influenza outbreaks (Goldfield,  Bartley,  Pizzuti, Black,  Altman,  
and  Halperin.  1977; Scholtissek, Burger, Kistner, and Shortridge. 1985). 
Until recently, direct avian-to-human transmission associated with fatal 
outcome in infected individuals was believed not to occur. But this was 
changed in 1997 when 18 individuals – six of whom died – were infected 
with H5N1 avian viruses in Hong Kong (Claas, Osterhaus, van Beek, De 
Jong, Rimmelzwaan, Senne., Krauss, Shortridge, and Webster, 1998; 
Subbarao, Klimov, Katz, Regnery, Lim, Hall, Perdue, Swayne, Bender, 
Huang, Hemphill, Rowe, Shaw, Xu, Fukuda and Cox. 1998). Since then, 
direct avian-to-human transmission has been reported in several other 
incidents, such as human infection with H7N7 avian virus in the 
Netherlands in 2003 (Fouchier,  Schneeberger,   Rozendaal,  Broekman,   
Kemink,   Munster,  Kuiken,  Rimmelzwaan,   Schutten,  Van Doornum , 
Koch,  Bosman ,  Koopmans  and  Osterhaus .  2004 ; Koopmans,  
Wilbrink, Conyn ,  Natrop,  van der Nat,  Vennema,  Meijer,  van 
Steenbergen ,  Fouchier, Osterhaus  and Bosman .  2004), or H5N1 avian 
viruses in Hong Kong in 2003 (Peiris,  Yu ,  Leung,   Cheung ,  Ng,    
Nicholls,  Ng,  Chan ,  Lai,  Lim ,  Yuen,  and  Guan .  2004), and in 
Vietnam and Thailand where 42 cases and 30 deaths were reported 
through September of 2004 (Tran, Nguyen, Nguyen, Luong, Pham,   Mai, 
Nguyen , Pham , Vo Cong,  Quynh , Dao, Nguyen , Hoang , Cao , 
Nguyen, Nguyen , San., Christiane, Tran, de Jong , Constance , Peter, 
Wilina, Peter, and Jeremy . 2004). 
1.2.2     History of the disease in Sudan: 
         Influenza-like diseases have been known to occur in the Sudan for a 
long time, but the true nature of these diseases has not been investigated. 
In 1957 there was an epidemic of an influenza-like disease which 
physicians attributed it to the Asian influenza type of virus that causing 
epidemics in other countries at the same time. However, no virus 
isolation or serological studies were performed in the Sudan at that time.  
In the winters of 1968-69 and 1969-70, there were epidemics of an 
influenza-like disease throughout the country, and laboratory 
investigations were carried out to establish the nature of the causative 
organism(s) of these epidemics (Salim, 1971). The first description of 
avian influenza disease was reported in 1925 on Sudan Veterinary 
Services annual report. But all of experimental surveys among fowl with 
respiratory diseases, to isolate the virus, were unable to isolate the virus 
(El Mubarak, 1970). 
       Then, Gafar and Kheir (1985) reported influenza ribonucleic protein 
antibody in the sera from different animal's species; camel, goat, sheep 
and cattle at eastern Sudan- Kassala using agar-gel immuno-diffusion test 
(AGID). Avian influenza (AI) antibodies have been detected in Sudan by 
(Manal, 2000 and Wegdan, Kheir and Ballal. 2007). Manal used AGID 
and Competitive ELISA tests to investigate the presence of avian, H1N1 
and H3N2, subtypes in some of Khartoum state chickens farms, and she 
found that 28.4% of test sera were positive for influenza type A. On the 
other hand, Wegdan used indirect ELISA to detect influenza type A 
antibodies in chicken’s sera collected from different regions of Sudan. 
Wegdan detect A1 virus type A antibodies in 911 serum samples out of 
1054(86.4%) in young and adult chickens. On the eighth of May 2006, 
the OIE reported the presence of H5N1 avian influenza in Sudan. 
Outbreaks have been reported in Atbara in River Nile State and in four 
poultry farms in Gezira State. Further information about the outbreaks 
has been requested by the OIE, and this was the first confirmation of 
H5N1 infection in Sudan, although the presence of the H5 subtype of 
avian influenza in Khartoum and Gezira States was reported by the OIE 
on 20 April 2006. The latest studies showed and indicated widespread of 
avian influenza type A antibodies in different localities in Sudan 
(Wegdan et al., 2007). 
1.3 Characteristic of Influenza viruses: 
      Influenza virions are pleomorphic, often spherical but 
predominantly filamentous in fresh isolates, 80-120 nm in their 
smallest dimension (Hoyle, 1968, Murphy et al., 1999).  Despite their 
distinctive shape, the filamentous virions possess many of the 
serological, hemagglutinating, and enzymatic characteristics of the 
spherical particles. The morphology of influenza virions seems to be 
primarily determined by the M gene (Bourmakina and Garcia-Sastre 
,2003; Roberts and Compans ,1998), although both the HA and NP 
genes are likely contribute (Jin, Leser, Zhang and Lamb. 1997; 
Mitnaul, Castrucci, Murti, and Kawaoka. 1996 ; Smirnov, Kuznetsova, 
and Kaverin. 1991). 
           Influenza A and B viruses are enveloped viruses with a segmented 
genome made of eight single-stranded negative RNA segments of 890 to 
2,341 nucleotides each (Gürtler, 2006).  The A and B types are 
distinguished by two integral membrane glycoproteins, HA and NA, that 
protrude from the virion surface. A third transmembrane protein, encoded 
by the M2 gene of influenza A viruses and the BM2 gene of influenza B 
viruses, serves as an ion channel, and within the lipid envelope exists the 
matrix (M1) protein. The RNA segments are associated with 
nucleoprotein (NP) and three large polymerase proteins, designated PA, 
PB1,and PB2 on the basis of their overall acidic or basic amino acid 
composition, that are responsible for RNA replication and transcription 
(Krug, Alonso-Caplen, Julkunen and Katze. 1989).           The HA spikes 
are rod-shaped, whereas the NA spikes resemble mushrooms with slender 
stalks. They are not distinguishable by electron microscopy unless either 
the HA or NA is removed from the virion surface with a protease or 
rosettes of the HA and NA are formed after virions are treated with 
detergent. The NA distribution on virions remains uncertain, but if the 
HA is removed with trypsin, the NA seems to be evenly distributed 
(Erickson and Kilbourne, 1980). However, by immunoelectron 
microscopy with monoclonal antibodies, but not polyclonal antibodies, it 
seems to be clustered (Amano, Uemoto, Kuroda and Hosaka, 1992; Murti 
and Webster, 1986).    
1.4   Virion properties: 
        Studies on influenza viruses have long been in the forefront of work 
on virus structure. The influenza virus was one of the first viruses to be 
studied in the electron microscope (Taylor, Sharp, Beard, Beard, Dingle, 
and Feller. 1943), and it demonstrated that certain viruses were assembled 
by budding from cell membrane (Murphy and Bang, 1952).  
1.4.1 Biological properties: 
      Hirst (1941) and McClelland and Hare (1941) discovered that 
influenza virus particles agglutinate the erythrocytes of fowl as well as of 
other animal species.This advance established the concept of 
hemagglutinin inhibition in the detection of specific serum antibodies, 
making it possible to distinguish between viruses of the same type. Hirst 
(1950) further demonstrated the presence of a receptor-destroying 
enzyme, now known as neuraminidase. Later biochemical work 
(Gottschalk, 1957) revealed that influenza viruses contain the HA and 
NA as major structural and antigenic components of the virus particle. 
     Influenza A and B virus HAs bind to oligosaccharide containing 
terminal sialic acids (Weis, Brown, Cusack, Paulson, Skehel and Wiley. 
1988). Topologically, the binding site is a depression and the amino acid 
residues that contact the terminal sialic acids , are highly conserved 
among the different HA subtypes (Nobusawa,  Aoyama, Kato,  Suzuki,  
Tateno and Nakajima .1991). The receptor specificity of the HA differs 
among influenza A viruses. Most avian and equine influenza viruses bind 
preferentially the NeuAcα2, 3Gal linkage, whereas human and classic 
H1N1 swine influenza viruses preferentially bind the NeuAcα2, 6Gal 
linkage on the cell surface sialyloligosaccharides (Rogers and Paulson. 
1983; Rogers, Pritchett, Lane and Paulson. 1983; Rogers and D’Souza 
.1989). 
         However, an avian H5N1 virus isolated from an individual in Hong 
Kong in 1997 bound to NeuAcα2, 3Gal-containing receptors but not to 
those containing an NeuAcα2, 6Gal linkage (Matrosovich, Zhou, 
Kawaoka and Webster. 1999), indicating that receptor specificity, while 
being an important determinant of host range restriction, does not prohibit 
avian-to-human transmission. 
1.4.2 Physical properties: 
        Influenza viruses can remain infectious after 24 to 48 hours on 
nonporous environmental surfaces and less than 12 hours on porous 
surfaces (Bean, 1982).  Influenza A viruses can persist for extended 
periods of time in water (WHO, 2006). One study of subtype H3N6 found 
that virus resuspended in Mississippi River water was detected for up to 
32 days at 4°C and was undetectable after 4 days at 22°C (Webster, 
1978). Another study found that several avian influenza viruses persisted 
in distilled water for 207 days at 17°C and 102 days at 28°C (Stallknecht, 
1990).  Recent data from studies of H5N1 in domestic ducks have shown 
that H5N1 can survive in the environment for 6 days at 37ºC (WHO, 
2004).  
       Inactivation of the virus occurs under the following conditions: 
temperatures of 56ºC for 3 hours, 60ºC, or more, for 30 minutes, acidic 
pH conditions, presence of oxidizing agents such as sodium dodecyl 
sulfate, lipid solvents, β-propiolactone and exposure to disinfectants such 
as formalin and iodine compounds(OIE, 2002). 
1.4.3   Chemical properties 
        The chemical composition of influenza virions can not be given with 
absolute precision because of the heterogeneity of the virus population 
and the fact that the composition of the virions is part dependent on the 
host cell with regard to lipids and carbohydrates. Approximate 
composition; however, have been determined as follow, 
 0.8 -1.1% ribonucleic acid (RNA), 70-75% protein, 20-24% lipids and 
carbohydrates (Ada and Perry, 1954; Frommhagen, Knight and Freeman.   
1959; Blough, Weinstien, Lawson, and Kodicek. 1967). The exact 
molecular weight of influenza virions is also uncertain due to the 
heterogeneity of the population, and estimations have varied widely.  On 
the basis of electron microscope and sedimentation properties, estimates 
of 270x10 ⁿ to 290x10 ⁿ,(n =6), Daltons have been obtained (Lauffer and 
Stanley, 1944; Sharp, Taylor, Mclean, Beard and Beard. 1945; Schramm, 
1954).       
 
1.4.4   Replication of influenza A virus: 
       The replication cycle of influenza viruses has been studied most 
extensively with type A strain. Influenza A virus infects cells through 
binding of it's HA protein to the cell’s sialyloligosaccharide receptor. 
After binding, the attached virion undergoes endocytosis (White, 
Kartenbeck and Helenius. 1982). The low pH of the late endocytotic 
vesicle triggers a conformational change, in the cleavage-activated HA, 
initiating fusion of the viral and vesicular membranes (Skehel, Bayley, 
Brown, Martin, Waterfield, White, Wilson and Wiley. 1982). Fusion 
releases the contents of the virion into the cytoplasm of the cell 
(uncoating). Before fusion, M2 proteins (BM2 protein for type B viruses, 
and possibly NB for type B viruses), by ion channeling, introduce protons 
into the inside of the virion, exposing the core to low pH (Hay, 1992; 
Helenius, 1992; Pinto, Holsinger and Lamb. 1992; Sugrue, Belshe, and 
Hay. 1990). Such an event is thought to promote dissociation of the M1 
from the RNP by disrupting the low pH-sensitive interaction between 
these molecules (Zhirnov, 1990), allowing the RNP to migrate to the 
nucleus through the nuclear pore in an ATP-dependent manner (Kemler, 
Whittaker and Helenius. 1994; Martin and Helenius, 1991). Once the 
RNP migrates into the host-cell nucleus, the associated polymerase 
complexes begin primary transcription of mRNA (Krug, Broni and 
Bouloy. 1979), which requires cooperation with ongoing transcription by 
cellular RNA polymerase II. The process of mRNA synthesis begins with 
incorporation of a G residue complementary to the penultimate C residue 
on the vRNAs (Beaton and Krug, 1981; Kawakami and Ishihama, 1983). 
Chain elongation is carried out by the PB1 subunit, which contains four 
consensus motifs for nucleic acid polymerases (Argos, 1988; Biswas and 
Nayak ,1994; Ishihama and Barbier ,1994; Poch, Sauvaget, Delarue and 
Tordo. 1989) as well as nucleotide binding sites (Asano, Mizumoto, 
Maruyama, and Ishihama.  1995;  Asano and Ishihama, 1997; Romanos 
and Hay, 1984).         
           Transcription continues until it reaches the poly (A) addition site, 
located 15–22 nt from the 5' end of the vRNA. Three elements are critical 
for polyadenylation: first, is a stretch of uridines near the 5' end of the 
virion RNA (optimal with 5–7 residues and 16 nt from the 5' end), which 
serves as the poly (A) signal (Luo, Luytjes, Enami and  Palese. 1991 ; Li 
and Palese, 1994; Poon, Pritlove, Fodor and Brownlee. 1999 ; Zheng ,  
Lee,  Palese,  García-Sastre .1999), secondly, the RNA duplex of the 
promoter structure, and third are specific nucleotides near the 5' end of 
the vRNA (Pritlove, Poon, Devenish, Leahy and Brownlee. 1999). The 
primary transcripts are then used in the production of viral proteins by the 
cell’s cytoplasmic translation machinery. Three polymerase proteins 
which are: PA, PB1, and PB2, as well as NP, NS1, and NS2 proteins, are 
transported to the nucleus. The negative-strand genomic segment and the 
positive-strand antigenomic segments, but not viral mRNA, are coated 
with NP. NS1 inhibits the transport of cellular mRNA to the cytoplasm 
by binding to the poly (A) region (Qiu and Krug, 1994) and maximizing 
the availability of capped primers for viral mRNA synthesis. The 
products of viral mRNA synthesis change as infection proceeds which 
indicate a temporal form of regulation (Hay, Lomniczi, Bellamy and 
Skehel.1977). Early in infection, the synthesis of mRNAs encoding NP 
and NS1 dominates; later the production of mRNAs for HA, NA, and M1 
increases, while transcripts for the polymerase proteins are relatively low 
throughout the infection cycle, except at the earliest time (Hatada, 
Hasegawa, Mukaigawa, Shimizu and Fukuda. 1989). The relative 
amounts of mRNAs correlate with the amounts of their corresponding 
proteins, indicating that viral gene expression is regulated at the 
transcriptional level, in addition to the temporal control mechanisms 
governing the translational efficiency of viral mRNA (Yamanaka, 
Ishihama and Nagata. 1988; Yamanaka, Nagata and Ishihama. 1991). The 
production of full-length viral complementary RNA (cRNA) was 
believed to be delayed until viral protein had been synthesized. In this 
model, newly synthesized NP promoted ‘read-through’ of the poly (A) 
site, allowing the synthesis of cRNA transcripts (Beaton and Krug, 1986; 
Shapiro and Krug, 1988) which in turn serve as templates for the 
production of vRNA. Recent findings, however, suggest that cRNA 
synthesis occurs early in infection as well, at this time point, cRNA may 
be degraded rapidly by cellular nucleases, while increasing amounts of 
polymerase proteins may protect the cRNA later in infection (Vreede, 
Jung and Brownlee. 2004). Equimolar quantities of cRNA are 
synthesized throughout infection (Hay et al., 1977), indicating a lack of 
regulation of this process.       
1.5 Classification of Influenza viruses: 
       The Orthomyxoviridae family consists of five genera: 
          Influenzavirus A, Influenzavirus B, Influenzavirus C, Thogotovirus, 
which includes the Thogoto virus and Dhori virus, and Isavirus, which 
includes infectious salmon anemia virus (ISAV) (Klenk, Cox, Lamb,  
Mahy, Nakamura, Nuttall, Palese and Rott. 1995) Orthomyxoviruses 
(Greek: orthos, straight or correct; myxa, mucus) contain segmented, 
linear, and negative-sense (complementary to mRNA) single-stranded 
RNA. The number of RNA segments differs among the genera: eight for 
influenza A, B and ISAV, seven for influenza C, six for Thogoto virus, 
and probably seven for Dhori virus. Accordingly, influenza A and B 
viruses contain HA and NA activities in different glycoproteins, whereas 
influenza C viruses lack NA, containing instead a hemagglutinin–esterase 
fusion (HEF) protein (Van Regenmortel, 2000).  
    Currently, there are 16 recognized HA subtypes (Fouchier, Munster, 
Wallensten, Bestebroer, Herfst, and Smith. 2005), (H1, H2, etc.) and nine 
NA subtypes (N1, N2, etc.). The full nomenclature for each new isolate 
includes the type of virus, the host of origin (except for human), 
geographical site of isolation, strain number, and year of isolation (WHO 
Memorandum, 1980).  
1.5.1 H5N1: 
     In May 1997, an avian influenza A H5N1 virus infection resulted in 
the death of a 3-year-old child in Hong Kong. The child died from 
complications of influenza-associated pneumonia, including acute 
respiratory distress syndrome, Reye's syndrome, and multiorgan failure. 
(Rowe, Abernathy, Jean Hu-Primmer, Thompson, Lu, Lim, Fukuda, Cox 
and Katz.  1999). 
       Recent genetic characterization of H5N1 strains involved in the 
current panzootic has demonstrated two distinct phylogenetic clades 
(Webster, Peiris, Chen and Guan. 2006).  Clade 1 viruses have circulated 
primarily in Cambodia, Thailand, and Vietnam, and clade 2 viruses have 
circulated primarily in China and Indonesia and have spread westward to 
the Middle East, Europe, and Africa. Six different subclades of clade 2 
have been recognized; three of these are primarily responsible for recent 
human H5N1 cases. The most recent wave of outbreaks in Thailand (in 
July 2006) has been caused by viruses closely related to those have 
caused outbreaks in Thailand in 2004-2005 and to viruses recently 
circulating in southeast China (Chutinimitkul, Songserm, Amonsin, 
Payungporn, Suwannakarn, Damrongwatanapokin, Chaisingh, 
Nuansrichay, Theamboonlers and  Poovorawan. 2007) .  
       AI infections in birds are generally benign, and these viruses are 
often classified as low pathogenic. However, viruses of the H5 and H7 
subtypes are prone to develop into variants that are highly pathogenic for 
poultry (Alexander, 2000).  
         A less common mechanism of generation of HPAI viruses has been 
observed in H7 viruses , which incorporate amino acid sequences derived 
from theNP or M genes through recombination( Hirst, Caroline, Malachi, 
Coughlin, Moksa, Zeng, Smailus, Holt, Jones, Marra, Petric, Krajden, 
Lawrence, Annie, Chow, Skowronski, Tweed, Goh, Robert, Brunham, 
Robinson, Victoria, Sojonky, Sean Byrne, Li, Kobasa, Booth and Paetzel. 
2004 ; Suarez, Senne, Banks, Brown, Essen, Lee, Manvell, Mathieu-
Benson, Moreno, Pedersen, Panigrahy, Rojas, Spackman and Alexander. 
2004). Regardless of the mechanism of mutation, the result is a virus that 
spreads cell to cell, causing a systemic infection in birds. 
   Before 1997, it was believed that molecular constraints restricted the 
host range of HPAI viruses to infection of avian species. Since the 
description of HPAI virus infection in 1878 as “fowl plague,” there has 
never been any indication that the illness could be transmitted to humans, 
despite the multiple opportunities that have existed through the numerous 
outbreaks recorded in history. For example, both low and highly 
pathogenic H5 viruses have been circulating in Mexico since 1993 (Lee, 
Senne and Suarez. 2004) but no case of human infection with H5 AI was 
documented there. Although serologic studies in the United States and 
Europe provided evidence of human infections with various HA subtypes 
of avian influenza from poultry, these infections were generally 
subclinical. (Shortridge,  1992). 
          The H5N1 virus that was first shown to give rise to strains that can 
transmit to humans appears to have emerged in Southeast China. During 
1996, an AI outbreak was observed in geese in Guandong Province   The 
virus was identified as the H5N1 virus and was considered to be an HPAI 
by virtue of the cleavability of the HA and animal inoculation 
studies(Guo, Xu And Wan. 1998). The new H5N1 virus was transported 
to Hong Kong, where it caused a major HPAI outbreak in chickens and 
other birds and unexpectedly transmitted to humans (Claas et al., 1998, 
Subbarao et al., 1998).  Human cases of H5N1 have been reported and 
confirmed in Vietnam, Thailand, Cambodia, and Indonesia. (WHO, 
2005a).   
         Sustained human to human transmission has not been confirmed, 
but a probable case of limited transmission within a family was recently 
described in Thailand (Ungchusak,  Auewarakul,  Dowell,  Kitphati,  
Auwanit, Puthavathana, Uiprasertkul,  Boonnak,  Pittayawonganon,  Cox,   
Zaki ,  Thawatsupha,  Chittaganpitch,  Khontong,  Simmerman   and  
Chunsutthiwat. 2005). Experimental data found that cats are readily 
susceptible, transmit and die of infection with some H5N1 strains 
(Enserink and Kaiser 2004; Kuiken,  Rimmelzwaan, van Riel, van 
Amerongen, Baars,  Fouchier   and Osterhaus.   2004). This novel finding 
contrasts with previous reports that cats could be experimentally infected 
with human viruses without becoming ill or shedding the virus (Hinshaw, 
Webster, Easterday and Bean. 1981). More recently, an outbreak of 
H5N1 in tigers, with evidence of natural tiger-to-tiger transmission, was 
reported (Thanawongnuwech, Amonsin, Tantilertcharoen, 
Damrongwatanapokin, Theamboonlers, Payungporn, Nanthapornphiphat, 
Ratanamungklanon, Tunak, Songserm, Vivatthanavanich, 
Lekdumrongsak, Kesdangsakonwut, Tunhikorn and Poovorawan. 2005). 
Although not considered a major threat for transmission of H5N1 to 
humans, the infections of feline species highlighted our limited 
understanding of interspecies transmission. 
   Analysis of the NA sequences found a deletion of 20 amino acids in the 
stalk region of the molecule, which is commonly found in viruses adapted 
to terrestrial birds. Further analysis revealed that, since 1997, the NA 
gene has been replaced at least 3 times by phylogenetically distinct N1 
genes through constant reassortment, suggesting that other viral subtypes 
contribute to the perpetuation of the H5 viruses in Asia(Guan,  Peiris,   
Lipatov,   Ellis,  Dyrting, Krauss, Zhang,  Webster and Shortridge. 2002; 
Guan, Poon,  Cheung, Ellis, Lim, Lipatov, Chan, Sturm-Ramirez, 
Cheung, Leung , Yuen, Webster and Peiris. 2004). 
1.5.2    H7N3:           
      This subtype of avian influenza viruses was firstly isolated in 1963 in 
England where it caused infection for about 29,000 breeder turkeys and 
accordingly it was named as follow-  A/turkey/England/63 (H7N3), also 
in 1992 it was isolated again in Australia  from approximately 12,700 
broiler breeders and 5,700 ducks .And in 2004 in Canada- 
A/chicken/Canada-BC/ 2004(H7N3), caused infection to 53 flocks and 17 
million chickens leeding outbreaks with significant spread to numerous 
farms, resulting in great economic losses while most other outbreaks were 
associated with only restricted or no spread from the index 
farms(Alexander ,2000; Kamps, Hoffmann and Wolfgang. 2006).  
   Although all virulent strains, of avian influenza, isolated to date have 
been either of the H5 or H7 subtype, most H5 or H7 isolates have been of 
low virulence. Due to the risk of a low virulent H5 or H7 becoming 
virulent by mutation in poultry hosts, all H5 and H7 viruses have also 
been classified as Notifiable Avian Influenza (NAI) viruses (OIE, 2005).        
1.6   Mutation of Influenza virus: 
       The epidemiological success of influenza viruses is largely due to the 
two types of antigenic variation that occur in the HA and the NA.        
Antigenic variations in HA and NA proteins have resulted in the 
classification of type A influenza into subtypes (Wharton, Weis, Skehel, 
and Wiley. 1989), and respectively  renders an individual susceptible to 
infection with new strains , despite previous experience with other 
influenza viruses.  
   The first kind of variation, called antigenic drift, occurs with both 
influenza A and B viruses, and it is the gradual alteration of the structure 
of the protein by single amino acid substitutions (mutation) in the HA and 
NA within type B influenza viruses or within a given subtype of influenza 
A viruses. This kind of variation is the result of positive selection of 
spontaneous mutants by neutralizing antibodies (Bush, Bender, Subbarao, 
Cox and Walter. 1999; Plotkin and Dushoff, 2003). Recent phylogenetic 
analysis have also shown that, although co-circulating lineages of HA 
genes of influenza B viruses can co-exist longer than for influenza A 
hemagglutinin genes, the overall patterns and the rates of evolution of the 
HA genes of these two types of influenza viruses are more similar than 
was previously believed (Cox and Bender, 1995). 
          Only influenza A viruses exhibit the second, more dramatic kind of 
antigenic variation which called antigenic shift. Antigenic shift is the 
appearance of a new subtypes of influenza A viruses containing a novel 
HA, or a novel HA and NA, immunologically distinct from isolates 
circulating previously. When antigenic shift occurs, the HA of the new 
strain would be expected to vary at the amino acid level 20–50 percent 
from the corresponding protein of previously circulating strains. 
Antigenic shift is responsible for worldwide pandemics, which occur at 
irregular and unpredictable intervals. 
Although 16 subtypes of influenza HA have been identified in avian 
species, epidemics and pandemics of influenza among humans during this 
century seem to have been caused by viruses with HAs of only three 
different subtypes: H1, H2, and H3.  While the pandemic human 
influenza viruses of 1957 (H2N2) and 1968 (H3N2) clearly arose through 
reassortment between human and avian viruses, the influenza virus 
caused the Spanish flu in 1918 ,which was the most severe recorded 
pandemic of influenza, appears to be entirely derived from an avian 
source (Reid,  Taubenberger  and Fanning. 2004; Belshe, 2005). 
1.7    Transmission: 
            Human influenza is transmitted by inhalation of infectious 
droplets and droplet nuclei by direct contact, and perhaps, by indirect 
(fomite) contact, with self-inoculation onto the upper respiratory tract or 
conjunctival mucosa. (Salgado, Farr, Hall and Hayden. 2002). 
The relative efficiency of the different routes of transmission has not been 
defined. For human influenza A (H5N1) infections, evidence is consistent 
with bird-to-human, possibly environment-to-human, and limited, non 
sustained human-to-human transmission to date (Bridges, Kuehnert and 
Hall.  2003).    
1.7.1 Animal to Human: 
        In 1997, exposure to live poultry within a week before the onset of 
illness was associated with disease in humans, whereas there was no 
significant risk related to eating or preparing poultry products or exposure 
to persons with influenza A (H5N1) disease. (Mounts,  Kwong,  Izurieta,  
Ho,  Au,  Lee,  Buxton,  Williams,  Mak, Katz,  Thompson, Cox and 
Fukuda.  1997). Exposure to ill poultry and butchering of birds were 
associated with seropositivity for influenza A (H5N1) (Bridges, Lim, Hu-
Primmer, Sims, Mak, Fukuda, Rowe, Thompson, Conn, Lu, Cox and 
Katz. 2002).  
1.7.2 Human to Human: 
      Human-to-human transmission of influenza A (H5N1) has been 
suggested in several household clusters and in one case of apparent child-
to-mother transmission (Ungchusak et al., 2005). Intimate contact without 
the use of precautions was implicated, and so far no case of human-to-
human transmission of H5N1 virus by small-particle aerosols has been 
identified. In 1997, human-to-human transmission did not apparently 
occur through social contact, (Katz, Lim, Bridges, Rowe, Hu-Primmer, 
Lu, Abernathy, Clarke, Conn, Izurieta, Kwong, Mak and Cox. 1999), and 
serologic studies of exposed health care workers indicated that 
transmission was inefficient (Bridges, Katz, Seto, Chan,  Tsang,  Ho, 
Mak,  Lim, Tam,  Clarke, Williams,  Mounts, Bresee,  Conn,  Rowe,    
Hu,  Abernathy,  Lu,  Cox,   and Fukuda. 2000).                                       
1.7.3    Environment to Human: 
         Given the survival of influenza A (H5N1) in the environment, 
several other modes of transmission are theoretically possible. Oral 
ingestion of contaminated water during swimming and direct intranasal or 
conjunctival inoculation during exposure to water are other potential 
modes, as is contamination of hands from infected fomites and 
subsequent self-inoculation. The widespread use of untreated poultry 
feces as fertilizer is another possible risk factor (WHO. 2005b). 
1.8 Clinical features: 
       The clinical spectrum of influenza A (H5N1) in humans is based on 
descriptions of hospitalized patients. The frequencies of milder illnesses, 
sub clinical infections, and a typical presentations (e.g., encephalopathy 
and gastroenteritis) have not been determined, but case reports indicate 
that each occurs. Most patients have been previously healthy young 
children or adults. (Apisarnthanarak, Kitphati, Thongphubeth, 
Patoomanunt, Anthanont, Auwanit, Thawatsupha, Chittaganpitch, Saeng-
Aroon, Waicharoen, Apisarnthanarak, Storch, Mundy and Fraser. 2004; 
WHO. 2005c; De Jong, Cam, Qui, Hien, Thanh, Hue, Beld, Phuong, 
Khanh, Chau, Hien,  Ha and  Farrar. 2005).  
 
 
 
1.8.1. Incubation: 
       The incubation period of avian influenza A (H5N1) may be longer 
than for other known human influenzas. In 1997, most cases occurred 
within two to four days after exposure (Yuen, Chan, Piris, Tsang, Que, 
and Shortridge, 1998); recent reports indicate similar intervals but with 
ranges of up to eight days. The case-to-case intervals in household 
clusters have generally been 2 to 5 days, but the upper limit has been 8 to 
17 days, possibly owing to unrecognized exposure to infected animals or 
environmental sources (Chotpitayasunondh, Ungchusak, 
Hanshaoworakul, Chunsuthiwat  and Sawanpanyalert. 2005 ; Hien, Liem,  
Dung,  San,  Mai,  Chau,  Suu,  Dong,  Mai,  Thi,  Khoa,  Phat,  Troung,  
Long,  Tung,  Giang,   Tho,   Nga,   Tien,   San,   Tuan,  Dolecek,   
Thanh,   Jong,   Schultsz,   Cheng,    Lim,   Horby  and  Farrar.  2004).             
1.8.2. Initial Symptoms: 
     Most patients have initial symptoms of high fever (typically a 
temperature of more than 38°C) and an influenza-like illness with lower 
respiratory tract symptoms (WHO. 2004). Upper respiratory tract 
symptoms are present only sometimes. Unlike patients with infections 
caused by avian influenza A (H7) viruses, patients with avian influenza A 
(H5N1) rarely have conjunctivitis(Fouchier et al.,2004). Diarrhea, 
vomiting, abdominal pain, pleuritic pain, and bleeding from the nose and 
gums have also been reported early in the course of illness in some 
patients (Chan, 2002; Chotpitayasunondh et al., 2005; Hien et al., 2004; 
Tam, 2002). Watery diarrhea without blood or inflammatory changes 
appears to be more common than in influenza due to human viruses 
(Nicholson, 1998), and may precede respiratory manifestations up to one 
week (Apisarnthanarak et al., 2004). One report described two patients 
who presented with an encephalopathic illness and diarrhea without 
apparent respiratory symptoms (De Jong et al., 2005). 
1.8.4. Mortality: 
      The fatality rate among hospitalized patients has been high, although 
the overall rate is probably much lower (WHO. 2005c).  In contrast to 
1997, when most deaths occurred among patients older than 13 years of 
age, recent avian influenza A (H5N1) infections have caused high rates of 
death among infants and young children. The case fatality rate was 89 
percent among those younger than 15 years of age in Thailand. Death has 
occurred in an average of 9 or 10 days after the onset of illness, and the 
range was 6 to 30, and most patients have died of progressive respiratory 
failure (Chotpitayasunondh et al., 2005; Hien et al., 2004). 
1.9 Pathogenicity: 
                Much remains to be learned about the pathogenesis of influenza virus 
replication and its relationship to the clinical manifestations and 
complications of the infection.  Many studies to investigate the 
pathogenesis of influenza infections were conducted during the 1957/8  
         pandemic of Asian influenza (Hers and Mulder, 1961 ; Walsh, Dietlein,    
Low, Burch   and Mogabgab. 1961). These studies demonstrated that the 
principal site of replication is the columnar epithelial cells, but 
histological studies indicate that viral replication can occur throughout 
the respiratory tract. Infected ciliated columnar cells become vacuolated 
and lose their cilia, and infected mucosal and ciliated epithelial cells 
become necrotic and desquamate. Regeneration of the respiratory 
epithelial cells takes about 3–4 weeks, during which time pulmonary 
function abnormalities may persist (Hall, Douglas, Hyde, Roth, Cross, 
and Speers. 1976). In these typical cases of influenza in which infection is 
confined to the respiratory tract, prostration, fever, and myalgia often 
seem to be disproportionate to objective clinical signs or observed 
pathological changes. Lungs from fatal cases of primary viral pneumonia 
most notably show hyaline membrane coverage of alveolar walls together 
with extensive intra-alveolar edema and hemorrhage. Tracheitis and 
bronchitis are also observed (Hers and Mulder, 1961; Martin,  Kunin,   
Gottlieb,  Barnes,  Liu and Finland. 1959). The occurrence of systemic 
illness and fever suggests dissemination of virus via the blood stream, but 
systematic studies (Kilbourne, 1959; Minuse, and Willis. 1962) and 
limited case reports (Lehmann and Gust, 1971; Naficy, 1963) suggest that 
viremia is detected only rarely. 
1.10   Diagnosis:  
     A number of techniques have been developed for the diagnosis of 
influenza virus infections. Virus isolation in cultured cells or in fertilized 
hens’ eggs or demonstration of a four-fold or greater rise in specific 
antibodies between acute and convalescent sera are techniques that have 
been used for many years. More recently, detection of viral antigens 
directly in clinical specimens by immunological methods and detection of 
viral nucleic acids by hybridization or using polymerase chain reaction 
(PCR) has greatly increased the speed of laboratory diagnosis. 
1.10.1    Isolation of the viruses: 
    The historical record of influenza viruses remained sparse until 
technological advances permitted their isolation. In 1901, a ‘filterable 
agent’ was isolated from chickens suffering from fowl plague which was 
later classified by Schafer (1955) as influenza A virus. Smith, Andrews 
and Laidlaw (1933), inoculated ferrets intranasally with human 
nasopharyngeal washes, which produced a form of influenza that spread 
to the animals’ cage mates.  
   An antigenically distinct virus, isolated by Francis (1940), was 
classified as a type B strain (B/Lee/40) to distinguish it from the 1933 
isolate. The third major type of influenza virus, influenza C, was first 
isolated in 1947 by Taylor (Taylor, 1949). 
   Embryonated hens’ eggs, a number of primary tissue culture systems 
and continuous cell lines, such as Madin– Darby canine kidney (MDCK, 
American Type Culture Collection, Rockville MD), cells can be used to 
isolate and grow influenza viruses for identification or research purposes. 
On initial passage in eggs or tissue culture, some influenza viruses 
preferentially agglutinate guinea-pig over chicken erythrocytes, but on 
continued passage the viruses may preferentially agglutinate erythrocytes 
from chickens (Burnet and Bull, 1943). 
1.10.2-    Isolation in Embryonated Eggs: 
      Soon after the first identification of human influenza A viruses, 
Burnet (1936) reported that embryonated hens’ eggs could serve as a host 
system for their propagation. This host system is still used for vaccine 
production and for generating large quantities of influenza virus that are 
occasionally necessary for research. To isolate both type A and type B 
influenza viruses, clinical samples are inoculated into the amniotic and 
allantoic cavities of 10– 11-day-old embryonated hens’ eggs. The eggs 
are usually incubated at 33˚–34˚_C for 2–3 days before the virus is 
harvested.     Most type A and B influenza viruses that are originally 
isolated in eggs will grow well in the allantoic cavity after one or two 
passages. Type C influenza viruses, on the other hand, grow only in the 
amniotic cavity and are best propagated in 7–8-day-old embryonated 
hens’ eggs after 5 days’ incubation (Burnet and Bull, 1943).  
1.10.3 Isolation in Tissue Culture: 
     Primary cynomolgus or rhesus monkey kidney cells (PMKC) are 
susceptible to a variety of respiratory viruses, including influenza viruses.      
Disadvantages with these cells include their cost and the presence of 
spumaviruses. Influenza A, B, and C viruses can also be isolated in the 
MDCK cell line in the presence of trypsin. Primary monkey kidney and 
MDCK cells are most often used for the primary isolation of influenza 
viruses from humans. 
     Influenza virus isolation in tissue culture is still used in many 
laboratories worldwide and when performed correctly, with properly 
collected specimens along with good quality laboratory cells and 
reagents, this method is highly sensitive. The shell vial tissue culture 
isolation method combines rapid detection of virus in the inoculated cells 
after 48– 72 h, increased sensitivity being obtained by centrifugation of 
specimens onto the cells. Monoclonal antibodies are often used for 
immunofluorescent detection of viral antigens in the inoculated cells 
(Kalin and Grandien, 1993).  
1.10.4   Serology: 
        Serologic testing can be used for retrospective diagnosis of infection 
but is rarely useful for patient management and is not widely available 
(Hayden and Palse. 2002; Treanor, 2005). Acute-phase sera should be 
collected within 1 week after illness onset and convalescent sera should 
be collected 2 to 3 weeks later.  
      The most common serologic methods are complement fixation (CF) 
Agar-gel immunodiffusion (AGID), Hemagglutination inhibition (HI) 
tests, and enzyme-linked immunosorbent assay (ELISA). A variety of 
other methods, such as neutralization, microneutralization, single radial 
hemolysis, radial immunodiffusion, and Western blot, have been reported 
(Hayden and Palse. 2002; Rowe et al., 1999).  
 
 
 
1.10.4.1      Agar gel-immunodiffusion test (AGID): 
      All influenza A viruses have antigenically similar nucleocapsid and 
antigenically similar matrix antigens (OIE, 2005). This fact enables the 
presence or absence of antibodies to any influenza A virus to be detected 
by AGID  test that have been widely and routinely used to detect specific 
antibodies in serum as an indication of infection. These have generally 
employed nucleocapsid-enriched preparations made from the 
chorioallantoic membranes of embryonated fowl eggs   that have been 
infected at 10 days of age, homogenised, freeze–thawed three times, and 
centrifuged at 1000 g. The supernatant fluids are inactivated by the 
addition of 0.1% formalin or 1% betapropiolactone, recentrifuged and 
used as antigen (Beard, 1970).   
 
1.10.4.2 Haemagglutination (HA) and Haemagglutination Inhibition 
(HI) tests: 
         Variations in the procedures for HA and HI tests are practised in 
different laboratories. The following recommended examples are applied 
using U-bottomed micro-well plastic plates in which the final volume for 
both types of test is 0.075 ml. The reagents required for these tests are 
isotonic PBS (0.1 M), pH 7.0–7.2, and red blood cells (RBCs) taken from 
a minimum of three SPF chickens and pooled in an equal volume of 
Alsever’s solution. Cells should be washed three times in PBS before use 
as a 1% (packed cell v/v) suspension (OIE, 2005).  
 
 
 
 
 
1.10.4.2.1    Haemagglutination (HA) test: 
            The surface HA glycoprotein of influenza virus isolates will bind 
to variety of mammalian and avian erythrocytes, and this phenomenon is 
the basis for screening of 9 days old inoculated allantoic fluids for the 
presence of agglutinating agents. Hemagglutination is determined by 
making twofold serial dilution in a microtiter plate followed by the 
additioin of an equal volume of 1% washed chicken erythrocytes. 
Diluting the allantoic fluid avoids the occasional prozone phenomenon 
that can occur with undiluted egg fluids (WHO, 2002; Swayne, Senne 
and Beard. 1998). 
1.10.4.2 .2   Haemagglutination Inhibition (HI) test:  
      The hemagglutination inhibition (HI) assay, the standard method for 
serologic detection of influenza virus infection in humans, has been 
shown to be less sensitive for the detection of antibodies induced by avian 
influenza viruses (Lu, Webster and Hinshaw 1982; Rowe et al., 1999). 
Because of the instability of HA, the dilution of antigen used must be 
precisely determined by HA titration each time the HI test is performed. 
The test is also complicated by the presence in sera of several species of 
nonspecific inhibitors of hemagglutination(WHO, 2002). These inhibitors 
interact with the HA molecule and prevent the agglutination of 
erythrocytes, even in the absence of specific antibodies. The non-specific 
inhibitors fall into three classes: (α) inhibitors, which are present in 
human serum and are heat-stable sialylated glycoproteins that inhibit 
hemagglutination but do not neutralize viral infectivity; (β) inhibitors, 
which are also present in human serum but are heat-labile and have 
neutralizing activity; and (γ) inhibitors, which are present in horse serum 
and are heat stable sialylated sialoproteins with neutralizing activity.  A 
variety of techniques to inactivate serum inhibitors have been developed. 
These include treatment with heat, receptor-destroying enzyme (RDE) of 
Vibrio cholerae, trypsin, periodate, or a combination of these factors 
(Kendal, Skehel and Pereira. 1982).  
1.10.4.3    Enzyme Linked Immunosorbent Assay (ELISA): 
Competitive ELISA formats allow the examination of sera of all bird 
species, independent from the availability of species-specific conjugates 
(Shafer, Katz, Eernisse. 1998; Zhou, Chan, Heckert and Cantin. 1998). 
An ELISA format for the detection of H7-specific antibodies has been 
reported (Sala, Cordioli, Moreno-Martin, Tollis, Brocchi, Piccirillo and 
Lavazza. 2003). 
1.10.4.4   Immunofluorescence: 
      For direct immunofluorescence, potentially infected respiratory 
epithelial cells are fixed to a slide and viral antigens contained in the cells 
is detected by specific antibodies which are either directly conjugated to a 
fluorescent dye (direct immunofluorescence) or detected by anti-
antibodies linked to a fluorescent dye (indirect immunofluorescence). In 
both cases reactions are visualised under the fluorescence microscope and 
positive cells are distinguished on colour intensity and morphology of 
fluorescent areas. Compared to complement fixation and AGID tests, 
immunofluorescence test was more sensitive and could be used as 
quantitative method for the detection of antibody to the RNA and surface 
antigens (Stumpa, Fedova and Tumova. 1975).  
1.10.4.5    Neuraminidase Inhibition (NI) test: 
      Influenza virus neuraminidase (NA) enzyme is important for the 
release of virions from the host cell surface and viral aggregates and may 
also be involved in ensuring that the virus is targeted to respiratory 
epithelial cells (Gubareva, Kaiser  and Hayden. 2000). 
              The major steps to perform the test include: 
(i)    Assays of the test virus for neuraminidase activity. 
(ii)  Adjustment of virus dosage to a standard unit of   neuraminidase 
activity.  
(iii)  Assays of the antibodies by testing serial dilution of the tested 
antiserum for inhibition of standard units of neuraminidase (Aymard, 
Coleman, Dowdle, Laver, Schild and Webster. 1973). 
 The neuraminidase inhibition test is performed by incubating the 
standard viral neuraminidase dose with serial dilution of normal and 
tested sera. The inhibitory effect serum on neuraminidase activity is 
determined and the neuraminidase inhibition titer is calculated.    
1.10.4.6    Complement Fixation (CF) test: 
      Complement fixation tests are based on the ability of antigen-
antibody complexes to consume complement which results in no 
compliment being available to lyse sensitized sheep red blood cells. 
These assays are intensive laborious and necessitate controls for each 
procedure but reagents are cheap and widely available. CF assays are less 
sensitive than HI both in the diagnosis of acute infection and the 
determination of immunity after vaccination (Prince and Laber. 2003). 
1.10.5 Molecular techniques: 
1.10.5.1 Reverse Transcriptase Polymerase Chain Reaction (RT- 
PCR): 
      Reverse transcriptase-Polymerase chain Reaction (RT-PCR) 
procedure have been developed to detect the presence of nucleic acid of 
influenza virus in clinical samples and to identify virulence markers 
associated with HPAI viruses in subtypes H5 and H7(Horimoto  and 
Kawaoka, 1995). Although detection of nucleic acid by RT-PCR 
procedures can aid in the presumptive diagnosis of avian influenza, 
isolation of the virus is required for subtype and pathogenicity 
determination .Virulence markers in H5 and H7 subtypes of avian 
influenza viruses have been characterized by the presence of multiple 
basic amino acids at the hemagglutinin cleavage site.  RT-PCR 
techniques on clinical specimens could, with the correctly defined 
primers, result in rapid detection and subtype (at least of H5 and H7) 
identification, plus a cDNA product that could be used for nucleotide 
sequencing (Munch, Nielsen, Handberg and Jorgensen. 2001; Starick, 
Romer-Oberdorfer and Werner. 2000; Suarez, 1998).  
1.11         Control of Influenza disease: 
1.11.1      Vaccination: 
       Vaccination is currently the most effective measure for reducing the 
impact of influenza among human or avians. Immunization against 
human influenza is focused mainly on individuals at increased risk of 
complications of influenza infection and on individuals who might 
transmit influenza to such people (Fedson, Hannoun, Leese, Sprenger, 
Hampson, Bro-Jorgensen, Ahlbom, Nokleby, Valle, Olafsson, Garcia, 
Gugelman, de Andrade, Snacken, Ambrosch and Isa. 1995; Nicholson, 
Snacken and Palache. 1995). 
        Experimental work has shown, for both highly pathogenic avian 
influenza (HPAI) and low pathogenic avian influenza (LPAI), that 
vaccination protects against clinical signs and mortality, reduces virus 
shedding and increases resistance to infection, protects from diverse field 
viruses within the same hemagglutinin subtype, protects from low and 
high challenge exposure, and reduces contact transmission of challenge 
virus (Swayne, 2003; Swayne and Suarez, 2000; Capua, Terregino, 
Cattoli and Toffan. 2004 ; European Union . 2003).  
     Long-term circulation of the virus in a vaccinated population may 
result in both antigenic and genetic changes in the virus and this has been 
reported to have occurred in Mexico (Lee et al., 2004). Conventionally, 
vaccines that have been used against HPAI or LPAI have been prepared 
from infective allantoic fluid inactivated by beta-propiolactone or 
formalin and emulsified with mineral oil.   Inactivated vaccine was 
prepared from the LPAI virus of H7N3 subtype responsible for a series of 
outbreaks in turkeys in Utah in 1995 and used, with other measures, to 
bring the outbreaks under control (Halvorson, Frame, Friendshuh and 
Shaw. 1998). Regarding humans, no influenza A (H5) vaccines are 
currently commercially available for humans. Earlier H5 vaccines were 
poorly immunogenic and required two doses of high hemagglutinin 
antigen content (Treanor,  Wilkinson, Masseoud,  Hu-Primmer, Battaglia,  
O'Brien, Wolff, Rabinovich,  Blackwelder  and Katz.  2001), or the 
addition of MF59 adjuvant (Nicholson,  Colegate,  Podda,  Stephenson, 
Wood and Zambon.  2001), to generate neutralizing antibody responses. 
A third injection of adjuvanted 1997 H5 vaccine variably induced cross-
reacting antibodies to human isolates from 2004 (Stephenson, Bugarini, 
Nicholson,  Podda,  Wood, Zambon  and Katz. 2005). Reverse genetics 
has been used for the rapid generation of nonvirulent vaccine viruses 
from recent influenza A (H5) isolates, (Webby, Perez, Coleman, Guan, 
Knight,  Govorkova, McClain-Moss,  Peiris, Rehg,  Tuomanen  and  
Webster. 2004), and several candidate vaccines are under study. One such 
inactivated vaccine with the use of a human H5N1 isolate from 2004 has 
been reported to be immunogenic at high hemagglutinin doses (Altman, 
2005). Studies with approved adjuvants like alum are urgently needed. 
Live attenuated, cold-adapted intranasal vaccines are also under 
development; these are protective against human influenza after a single 
dose in young children (Belshe,   Mendelman, Treanor,  King,  Gruber,  
Piedra, Bernstein,  Hayden,  Kotloff,  Zangwill,  Iacuzio  and Wolff.  
1998). 
 
 
1.12     Treatment: 
    Antivirals that commonly used in treatment of Influenza A subtypes 
infection in human are devided into two major groups:  
A- M2 Inhibitors: 
– Amantidine is only effective against influenza A, and some naturally 
occurring strains of influenza A are resistant to it, the compound has been 
shown to have both therapeutic and prophylactic effects. 
– Rimantidine is similar to amantidine but has fewer side effects. It is 
used both for treatment and prophylaxis of influenza A infection in 
persons one year or older.   Amantadine and rimantadine both  interfere 
with the replication cycle of all subtypes of type A but not type B 
influenza viruses  (Hayden ,1996 ; Van Voris and Newell ,1992), they 
inhibit the replication of influenza A viruses at low, clinically achievable 
concentrations of <1 µg/ml (Tominack and Hayden ,1987).    
B- Neuraminidase inhibitors: 
– Zanamivir, the first neuraminidase inhibitor available for clinical use, is 
effective against both influenza A and B. It must be administered by 
inhalation. It is used as treatment for influenza A and B in persons 12 
years or older but not for prophylaxis. 
– Oseltamivir, can be given orally. Shown to be effective and devoid of 
significant side effects in clinical trials.  The first involves inhibition of 
the acid mediated dissociation of the matrix protein from the RNP 
complex within endosomes early in replication; this dissociation is 
essential for initiating viral replication (Pinto et al., 1992; Sugrue et al., 
1990). A second effect on virus maturation relating to a low pH-mediated 
alteration of the HA protein during its transport to the cell surface occurs 
during the replication of certain avian influenza viruses (Ohuchi, Cramer, 
Vey, Ohuchi, Garten and Klenk. 1994; Sugrue et al., 1990; Takeuchi and 
Lamb, 1994). 
   Viral strains responsible for pandemics and epidemics in recent years 
have all been drug-sensitive (Hayden, 1996), but resistance to these 
compounds is readily selected by growth in the presence of these drugs 
either in vivo or in vitro. Resistant viruses seem to be pathogenic and can 
cause typical influenza, but resistant viruses are no more transmissible or 
virulent than strains sensitive to amantadine and rimantadine (Hayden, 
1996). Drug resistance develops rapidly in viruses exposed to amantadine 
or rimantadine, and may emerge during treatment.( Couch ,1996 ;  Acha, 
and  Szyfres, 2003 ; Harper, Fukuda, Uyeki, Cox and Bridges. 2004). 
Some of the H5N1 viruses isolated in 2004 in Asia have been resistant to 
amantadine and rimantadine. Laboratory studies have shown that 
influenza viruses can also become resistant to zanamivir and oseltamivir 
(Harper et al., 2004). 
Patients with suspected influenza A (H5N1) should promptly receive a 
neuraminidase inhibitor pending the results of diagnostic laboratory 
testing, but optimal dose and duration of treatment with neuraminidase 
inhibitors are uncertain, and currently approved regimens likely represent 
the minimum required. These viruses are susceptible in vitro to 
oseltamivir and zanamivir. (Leneva, Roberts, Govorkova, Goloubeva and 
Webster. 2000; Govorkova, Leneva, Goloubeva, Bush and Webster. 
2001). In contrast two isolates from the 1997 outbreak, recent human 
influenza A (H5N1) isolates are highly resistant to the M2 inhibitors, 
amantadine and rimantadine, and consequently, these drugs do not have a 
therapeutic role. Agents of clinical investigational interest for treatment 
include zanamivir, peramivir, long-acting topical neuraminidase 
inhibitors, ribavirin (Madren, Shipman and Hayden. 1995, Knight and 
Gilbert, 1987), and possibly, interferon alfa. (Baron and Isaacs, 1962).  
     In recent years, WHO and the governments of many countries have 
been stockpiling antiviral drugs, primarily Tamiflu, for prophylaxis  and 
treatment(Longini, Nizam, Xu, Ungchusak, Hanshaoworakul, Cummings 
and Elizabeth. 2005). Tamiflu is a popular choice for stockpiling, since it 
is available in both pill form and a drinkable liquid suspension (Normile, 
2006a). Supply of Tamiflu will be boosted further because a handful of 
generic drug makers have started producing their own version of Tamiflu 
with a sub-license from Roche Laboratories Inc (Normile, 2006b). For 
example, Roche Laboratories Inc. has granted sub-licenses to companies 
in China and India to manufacture Tamiflu for pandemic use. 
In November 2006, the US Food and Drug Administration revised the 
product labeling requirement of Tamiflu to include new warnings about 
the possibility of self-injury and delirium associated with the drug 
(Normile, 2006c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER TWO 
MATERIALS AND METHODS 
  2.1   Serum sample collection: 
        Two hundred and twenty two (222) serum samples were collected 
randomly in March 2007, from patients with no apparent clinical signs 
of influenza or other influenza like disease, in the laboratories of the 
Sudan Atomic Energy Commission (SAEC) in Khartoum. One venous 
sample of blood was taken from each patient by laboratory technicians 
in 5mL syringe and serum was left to separate. Extra separation process 
of sera was done in the laboratory by centrifugation which was followed 
by allocating of each serum sample into three different Eppindorff 
tubes. The details of collected samples are demonstrated in tables 1, 2 
and 3 below. 
 
Table 1: Frequency of collected human serum Samples by Gender.  
 
  
Gender No. of collected Percent  
  
Male  
 
43 
 
19.4 
  
Female  
 
179 
 
80.6 
  
Total 
 
222 
 
100.0 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2:  Frequency of collected human serum Samples by Age 
groups.  
 
Age group 
 Frequency  Percent 
  
Less than 20 
 
12 
 
5.4 
  
20 - 30 
 
85 
 
38.3 
  
31 - 40 
 
64 
 
28.8 
  
41 - 50 
 
35 
 
15.8 
  
51 - 60 
 
22 
 
9.9 
  
More than 60 
 
4 
 
1.8 
  
Total 
 
222 
 
100.0 
 
 
 
 
Table 3: Frequency of collected human serum Samples by Location.  
 
 
 
 
Location Frequency Percent 
  
Khartoum 
 
141 
 
63.5 
  
Omdurman 
 
81 
 
36.5 
  
Total 
 
222 
 
100.0 
 
  
 
 
 
2.2- Laboratory Work: 
2.2.1-Preparation and Sterilization of Glassware: 
           Pipettes, Petri dishes, pestles and mortars, sand, test tubes, forceps 
, scalpels and scissors , were sterilized in hot oven at 160˚C for two 
hours. 
Tips, Eppendorff tubes, bottles with rubber caps and buffer solutions 
were autoclaved at 120˚C for 15 minutes. Microtiter plates were washed 
with 1% NaOH to remove the traces of the RBCs completely and then 
they were put overnight in the same solution. The next day they were 
rinsed with tap water and kept in 1% HCl solution for two hours. Finally 
they were washed in four changes of deionized distilled water and left to 
dry at room temperature. At every test they were swabbed with a piece of 
cotton and phosphate buffer saline (PBS) solution.       
 2.2.2-Avian Influenza Antigens: 
        Reference strains of H5N1/Mallad/Neth/12/00 and H7N3/Mallad/ 
Neth/12/00 were donated by WHO Reference Laboratory in the United 
Kingdom. 
 2.2.3- Reference antisera: 
        Reference antiserum of the H5N/Mallad/Neth/12/00/Rabbit     
anti-sera, and H7N3/Mallad/Neth/12/00/Goat, antisera were also donated 
by WHO Reference Laboratory in the United Kingdom. 
2.2.4      Virus Propagation and Identification: 
2.2.4.1    Embryonated Egg Inoculation and Harvest: 
2.2.4.1.1 Inoculation of the Chorioallantoic Membrane (CAM):  
         A central spot that just at the top of the air cell was marked on a 13 
days old embryonated egg then a hole was made just to penetrate the 
shell and shell membrane. Another hole was made in an area that is free 
of blood vessels and by the side of the egg. The dropping of the 
membrane was verified in dark room by candling, then a rubber bulb 
was placed over the hole in the air cell to slowly aspirate air from the 
cell by releasing pressure on the deflated bulb, the suction caused false 
air cell to form in the area of the second hole. To deliver the inoculums 
on the chorioallantoic membrane (CAM), the tip of 1ml insulin syringe 
needle was inserted just within the shell and 0.2ml was inoculated into 
each embryonated eggs. The eggs were incubated at 37ºC, and were 
examined daily for 5 days.   
2.2.4.1.2 Harvest of Chorioallantoic Membranes (CAM):    
       After 3-6 days of incubation the shell was disinfected on the small 
end of the egg by 70% alcohol, and the end of the egg was cracked off by 
sterile forceps. The CAM was removed from the shell by sterile forceps. 
The presence of the virus was detected by the appearance of thickness 
and or hemorrhages of CAMs, which were then moved to sterile mortar 
and grounded carefully with the aid of sterile sand and PBS using a 
pestle. The suspension was then subjected to three times series of freezing 
and thawing followed by centrifugation at 1000/rpm for 10 minutes. The 
supernatant was then collected and checked for hemagglutination activity. 
2.2.4.1.3 Inoculation of Allantoic Cavity: 
           The embryonated eggs, which inoculated, were 9 days old that 
candled to determine the edge of the air sac.  A spot was marked, using a 
pencil, right in the opposite side of the air sac and about 2-4mm far from 
the edge. A cotton wool and 70 percent alcohol were used to swab the 
end of the inoculated eggs, and the alcohol was allowed to evaporate. A 
hole was pierced horizontally at the end of the embryonated egg at the 
marked inoculation spot. One mL insulin syringe was used to inoculate 
about 0.2 mL of the virus suspension, vertically, through the hole in the 
eggshell, into the allantoic cavity. The needle was withdrawn from the 
egg and the hole was sealed with melted wax. The inoculated eggs were 
incubated at 37˚C and checked by candling against light daily for five 
days. Embryos that died within 24 hour were discarded and the survivals 
were transferred to refrigerator and chilled at 4˚C overnight and then 
were harvested. 
 2.2.4.1.4 Harvest of Allantoic Fluids:  
         The top of each harvested embryonated egg was cleaned with 70% 
ethanol, and sterile forceps was used to break the egg shell over the air 
sac. Then the chorioallantoic membrane was punctured, and the 
allantoic membrane was pushed a side by the forceps. A rapid 
hemagglutination test was performed in a clean ceramic plate to check 
the presence of agglutinating agent. The allantoic fluid was then 
aspirated using 5ml syringe and transferred to sterile screw capped tube. 
The harvested fluid were then centrifuged at 1000/rpm for 5 minutes and 
stored at -20˚C.   
2.2.5    Hemagglutination and Hemagglutination Inhibition: 
  2.2.5.1 Preparation of 1% RBCs: 
    Blood was collected from the wing vein from a minimum of three 
healthy chickens in an equal volume of Alsever's solution using 5mL 
disposable syringe. The red blood cells (RBCs) were then transferred to 
a sterile tube and washed three times with PBS solution by centrifuging 
at 1000 rpm for about 5 minutes. After the last wash the RBCs pellet 
was collected and measured to prepare 1% suspension by diluting with 
PBS solution.  
 2.2.5.2-Hemagglutination test: 
      Microtiter plates with U-shaped bottoms and washed RBCs were 
used to determine the titer of the two viruses (H5N1, H7N3) each at it's 
time. 
 A volume of 50µL of PBS (pH 7.2) was added to all wells using a 
multichannel micropipette. Then the antigen was added to the first well 
in each row except the last two, which were filled with 100 µL as 
control negative wells. A serial twofold dilution was then made by 
transferring 50 µL from the first well, that containing the virus to the 
next well and the last 50 µL were discarded.   
Fifty microliter of 1% RBCs suspension were then added to these wells 
and mixed manually. The plates were incubated for 30 minutes at room 
temperature. The virus titer is considered the reciprocal of the last 
dilution that gave a complete hemagglutination.  
 2.2.5.3   Hemagglutination Inhibition test:  
       This test was done to insure that the antigens used are specifically H5 
and H7. Serial twofold dilutions of the reference antiserum to the two 
viruses (H5N1 and H7N3) were done in U-shaped micro titter plate in 
PBS solution. Then equal volumes of four hemagglutinating units 
(4HAU) were added and after incubation at room temperature for 30 
minutes RBCs were added and incubated again for 40 minutes.    
2.2.6       Serological tests:  
2.2.6.1    Agar gel-immunodiffusion test (AGID): 
2.2.6.1.2 Preparation of antigen for the AGID test: 
   This test was done basically according to the method that used by 
Beard (1970) with some modification from OIE (2005). 
 Preparations of nucleocapsid-rich antigen were obtained from 
chorioallantoic membranes for use in the AGID test. This method 
involves removal of the chorioallantoic membranes that collected 
previously, from infected embryonated eggs. The membranes are then 
homogenised or ground to a paste using pestle and mortar after the 
addition of suitable amount of phosphate buffer saline (PBS), with pH 7.2 
in intervals. This is subjected to three freeze-thaw cycles, followed by 
centrifugation at 1000 g for 10 minutes. The pellet is discarded and the 
supernatant is used as an antigen following treatment with 0.1% formalin. 
 
2.2.6.1.3 Preparation of agarose: 
         The method used is similar to that used by Beard (1970). 
A weight of 1 gram agarose and 0.8 grams of Sodium chloride (NaCl) 
were added to 100ml of deionized distilled water (D.D.W) in 1 liter 
sterile glass flask. The mixture was then boiled in microwave for two 
minutes until it became clear. A volume of 0.5ml phenol was added as                    
preservative. 
2.2.6.1.4    Performing the AGID test:   
2.2.6.1.4.1 Preparation of Plates:  
     About 20ml of liquefied agarose were dispensed in 100x15 mm Petri 
dishes to create about 2.8~3 mm thickness. The plates were left to cool on 
a leveling table in dust free environment at room temperature. After the 
agarose was hardened, the wells were cut out using a template and the 
diameter of each well was 5.0 mm, and the distance between the central 
and peripheral wells was 2.4 mm. Five patterns were cut in each plate and 
the agarose plugs were removed manually. Wells were sealed by drops of 
agarose as control step. 
2.2.6.1.4.2   Method for examination of samples with AGID: 
       Equal volumes of influenza A (H5N1) AGID antigen, that was 
prepared before, and 1% Sodium Dodecyl Sulphate (SDS) were mixed 
together to enhance the diffusion of the antigen. Then 50 µL from the 
mixture were transfered to the central wells of each pattern, using a 
micropipette, and a 50 µL of positive control serum was placed in one of 
the peripheral wells in each rosette as same as negative controls. The 
remaining wells were filled with the tested sera. 
   The plates were then covered and incubated in humid chamber at room 
temperature and examined daily, against light and dark background, for 
precipitation lines at least for 48 hours. Positive results were recorded and 
plates were stained by Comassi Brilliant Blue stain, to improve 
visualization.                    
2.2.6.1.4.3   Interpretation of the results: 
          Precipitin lines were detected after approximately 48 hours and 
observed using illuminator with a dark background from behind.         A 
specific, positive result is recorded when the precipitin line between the 
known positive control wells is continuous with the line between the 
antigen and the tested serum well. Crossed lines are interpreted to be due 
to the test serum lacking identity with the antibodies in the positive 
control well.   
2.2.6.2      Hemagglutination Inhibition test: 
2.2.6.2.1   Preparation of 4HAU of the virus: 
Microtiter plates with U-shaped bottoms and 1% washed chicken RBCs 
were used to determine the four hemagglutinating units (4HAU) of the 
antigens each time the test was performed. 
       A fifty µL of PBS (pH 7.2) were dispensed in all of the plate wells, 
followed by the addition of 50 µL from the antigen to the first well in 
each row except rows G and H which were filled with 100 µL of the 
RBCs as control wells. A serial twofold dilutions were made by 
transferring 50 µL from the first wells, which containing the antigens, 
using multichannel micropipette to the successive columns, and the last 
50 µL were discarded.  Then 50 µL of the RBCs suspension were added 
to each well, except control wells, and mixed by shaking manually. The 
plates were then incubated at room temperature for half an hour, and 
then were read. 
       The highest dilution of the virus which caused complete 
hemagglutination is considered the titration end point, and the titer was 
considered the reciprocal of the virus dilution in the last well with 
complete hemagglutination which also considered to be containing one 
hemagglutinating unit (1HAU). The dilution that containing 4HAU was 
then calculated. 
2.2.6.2.2   Pre-treatment of sera to remove non-specific inhibitors:            
    One sample of serum was collected from people without obvious 
clinical signs of influenza or other influenza like diseases. Treatment of 
sera with trypsin and heat was found to be one of the best methods for 
removing non-specific inhibitors in human sera (Sampaio and Isaacs 
1953). The trypsin solution was prepared by dilution of 10x2.5% 
concentrated trypsin to 0.04% in PBS at pH 7.2 .Fresh trypsin was 
prepared for each day test. 
2.2.6.2.3 Hemagglutination Inhibition Procedure: 
    The method used is that described by WHO (2002). A volume of 
25µL of PBS was dispensed into each well of a plastic U-bottomed 
microtitre plate. Then 25µL of the tested serum is added into the first 
well of each row of the plate.    
A serial twofold dilution was made of 25µL volumes of the serum across 
the plate followed by the addition of 25µL of 4 HAU containing virus 
suspension to each well and left for a bout 30 minutes at room 
temperature to accomplish antigen-antibody interaction. Subsequently  
a 25µL of 1% (v/v) chicken RBCs was added to each well and after 
gentle mixing, the RBCs were allowed to settle for about 40 minutes at 
room temperature.  
2.2.6.2.4 Interpretation of results: 
   The HI titre is the highest dilution of serum causing complete 
inhibition of 4 HAU of antigen and the validity of results were assessed 
against a negative control serum. The HI titres was regarded as being 
positive if there is inhibition at a serum dilution of 1/16 or more against 
4 HAU of antigen (OIE. 2005). 
 
  
CHAPTER THREE 
RESULTS 
 
3.1. Agar gel-immunodiffusion test (AGID): 
3.1.1. Preparation of Matrix and Nucleoprotein antigens for the 
AGID test: 
Hemorrhage, edema and thickness were observed on the harvested 
chorioallantoic membranes (CAMs) which were inoculated with AI virus 
(H5N1).These antigens when tested with hyperimmune serum gave 
strong precipitation lines. 
3.1.2 Serologic Survey for type A influenza antibodies using AGID 
test: 
Two hundred and twenty two serum samples collected from humans were 
tested by AGID test to investigate and determine the presence of type A 
influenza antibodies. 
       As demonstrated in (Table 4) there were 76 (34.2%) samples out of 
the 222 samples positive to type A. And as Table 5 shows, the range of 
ages for the positive results extended below 20 and over 60 years old, 
which means that all ages, are exposed to infection with influenza A 
virus.  
            
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Results of testing human sera by AGID test for the detection 
of influenza A antibodies: 
 
  Frequency Percent 
  
Negative  
 
146 
 
65.8 
   
Positive 
 
76  34.2 
   
Total 
 
222  
 
100.0 
 
Table 5: Cross tabulation between Age and results of AGID test for 
determination of influenza A antibodies:  
 AGID 
Age Negative Positive Total 
  
Less than 20 
 
9 
 
3 12 
   
20 – 30 
 
53 32 85 
   
31 – 40 
 
47 17 64 
   
41 – 50 
 
19 16 35 
   
51 – 60 
 
16 6 22 
   
More than 60 
 
2 2 4 
 
Total 
 
146 76 222 
  
  Table 6 shows the prevalence of type A influenza antibodies in human 
sera which was found to be 34.2% in the whole tested sera, and 46.9%, 
62% in Khartoum and Omdurman respectively. 
 
Table 6: Cross tabulation between Location and AGID test results 
for influenza A antibodies in human sera: 
Location 
 AGID 
Negative Positive Total 
      
         96
        
 45(46.9%) 
        
         141
  
 
Khartoum 
 
 
Omdurman 
       
         50   
       
 31(62%)
          
           81  
 
Total 
 
       146  76(34.2%)         222   
 
 
3.2 Hemagglutination test for dilution of virus and preparation of 
virus 4 HAU: 
      The results of hemagglutination test were obtained to determine AI 
viruses' titers and the 4 HAU which should be used in HI test. As Table 7 
shows the titer of H5N1 was found to be 7 log 2 and therefore the 4 HAU 
was calculated as 5 log 2. On the other hand, the titer of H7N3 was 6 log 
2 and the 4 HAU was 4 log 2. 
 
 
 
  
 
 
 
Table 7: Results of influenza A virus titration and dilution of the 
virus to prepare 4 HAU(s) for HI tests: 
 
AI virus 
 
Titer 
 
4 HAU 
 
H5N1 
 
7 log 2 
 
5 log 2 
 
H7N3 
 
6 log 2 
 
4 log 2 
     
3.3 Hemagglutination inhibition test: 
    To subtype the positive samples, that obtained by AGID test, 
hemagglutination inhibition (HI) test was applied using H5N1 and H7N3 
avian influenza viruses as antigens. 
     Table 7 concluded the results of all sera, which were tested for AI 
(H5) antibodies, and it was found that there were 13 (17.1%) positive 
serum samples out of 76 samples. While Table 8 showed that 8 of these 
positive samples were from Khartoum and the rest 5 were from 
Omdurman. And when the 76 serum samples tested again against AI (H7) 
antibodies there were only 5(6.57%) positive samples, as shown in Table 
9, three of them from Khartoum and the other two were from Omdurman, 
as in Table 10.  
 
 
 
 
 
 
 
 
Table 8: Results of HI test for type A avian influenza  AGID positive 
humans sera using avian influenza H5N1 as antigens. 
 
  Frequency Percent 
  
Negative                 63              82.9
   
Positive                 13              17.1
   
Total                 76             100.0
 
     
Table 9: Cross tabulation between Location and results of HI test   
for collected human sera using avian influenza H5N1 virus as 
antigen. 
 
Location 
 
HI for H5 
 
Negative Positive Total 
 
133 
 
8 
 
141 
  
 
 
Khartoum  
 
 
Omdurman 
 
76 
 
5 
 
81 
 
Total 
 
209 
 
13 
 
222 
 
Table 10:  Results of HI test for avian influenza type A  AGID 
positive humans sera using avian influenza H7N3 as antigens. 
 
  Frequency Percent 
  
Negative 
 
71 
 
93.43 
   
Positive 
 
5 
 
6.57 
   
Total 
 
76 
 
100.0 
       However, Tables 11 and 12 summarize the cross tabs between age 
and the HI test results of H5 and H7 respectively, and from these two 
tables we can realize that there was no H5 infection under 20 years old 
persons, and the majority(11 out of 13)of infections were ranged between 
20 and 50 years old. But in case of H7 there was one infection under 20 
years and the range of infection (4 out of 5) was between20 and 40 years.  
 
Table 11: Cross tabulation between Age and results of HI test   for 
collected human sera using avian influenza H5N1 virus as antigen. 
  
  HI for H5 
Age 
 
Negative Positive Total 
   
Less than 20 
 
12 
 
0 
 
12 
   
20 - 30 
 
79 
 
6 
 
85 
   
31 - 40 
 
63 
 
1 
 
64 
   
41 - 50 
 
31 
 
4 
 
35 
   
51 - 60 
 
21 
 
1 
 
22 
   
More than 60 
 
3 
 
1 
 
4 
 
Total 
 
209 
 
13 
 
222 
 
       
  
 
 
 
 
 
 
 
 
 
Table 12: Cross tabulation between Age and results of HI test   for 
collected human sera using avian influenza H7N3 virus as antigen. 
  
 
HI for H7 
 
  
Negative 
 Positive Total 
Age  
Less than 20 
 
11 
 
1 
 
12 
   
20 – 30 
 
82 
 
3 
 
85 
   
31 - 40 
 
63 
 
1 
 
64 
   
41 – 50 
 
35 
 
0 
 
35 
   
51 – 60 
 
22 
 
0 
 
22 
   
More than 60 
 
4 
 
0 
 
4 
 
Total 
 
217 
 
5 
 
222 
 
         
 Table 13: Titers of antibodies detected by HI test against H5 and H7 
avian influenza subtypes in the positive sera collected from humans.  
 
 
 
AI virus 
 
2 log 2 
 
3 log 2 
 
4 log 2 
 
5 log 2 
 
6 log 2 
 
Total 
 
H5N1 
 
0 
 
0 
 
0 
 
11 
 
2 
 
13 
 
H7N3 
 
0 
 
1 
 
0 
 
4 
 
0 
 
5 
 
 
 
 
 
 
 
Figure1: Results of AGID test for detection of influenza A antibodies 
in humans sera. 
 
 
 
 
 
 
Figure 2: Comparison between avian influenza A antibodies positive 
and negative results tested by AGID and location of  serum samples.  
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Figure 3: Cross tabulation between Age and avian influenza A 
antibodies detected by AGID test in human sera. 
 
 
 
 
 
 
Figure 4: Cross tabulation between Age and results of HI test   for 
collected human sera using avian influenza H5N1 virus as antigen. 
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Figure 5: Cross tabulation between Age and results of HI test   for 
collected human sera using avian influenza H7N3 virus as antigen. 
 
 
 
 
 
 
 
Figure 6: Cross tabulation between Location and results of HI test   
for collected human sera using avian influenza H5N1 virus as 
antigen.
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Figure 7: Cross tabulation between Location and results of HI test   
for collected human sera using avian influenza H7N3 virus as antigen 
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CHAPTER FOUR 
 
DISCUSSION 
 
      Human influenza viruses are members of Orthomyxoviridae family, 
which consists of the genera: influenza A, B, and C virus, and Thogoto 
virus. In humans, only influenza A and B viruses are of epidemiological 
interest (Kamps, Hoffmann and Wolfgang, 2006).  
          Avian influenza (AI) is a highly contagious disease caused by type 
A influenza viruses that are members of the genus Influenza A virus. 
Infection with low-pathogenic avian influenza viruses (LPAIV) usually is 
asymptomatic or it induces mild respiratory symptoms. Infection with 
highly pathogenic avian influenza viruses (HPAIV) is characterized by 
the sudden onset of fatal systemic disease in susceptible species (OIE, 
2005). Avian influenza A viruses, including those that are highly 
pathogenic in poultry, have not previously been associated with 
respiratory disease in humans, although H7 viruses have been associated 
with unrelated cases of human conjunctivitis (Webster, Geraci , Petursson 
and  Skirnisson., 1981; Kurtz , Manvell and Banks, 1996). 
      In the last decade influenza diseases attracted a great world attention, 
since the first studied and documented human infection with H5N1 avian 
influenza virus that occurred in a 3-year-old male resident of Hong Kong 
who died in May 1997 of acute respiratory distress syndrome and 
complications.  
      According to the serological survey that was recently done (Wegdan 
et al., 2007), it can be concluded that there is a great widespread of AI 
among chicken in Sudan. Wegdan et al(2007) detect AI virus type A 
antibodies in 911 serum samples out of 1054 that were collected from 
young, growing and adult unvaccinated chicken flocks at Khartoum State, 
Central, Northern, Eastern and western Sudan during 2003 to early 2006. 
      In the present study a total of 222 serum samples were collected from 
human, without apparent clinical manifestations of influenza or 
influenza-like diseases, by three different laboratories of Sudan Atomic 
Energy Commission (SAEC) in Khartoum (n=141) and Omdurman 
(n=81).  
        All collected sera were tested by AGID test to investigate the 
prevalence of type A influenza antibodies in Khartoum state.  Over all 
results showed that: 76 serum samples out of 222(34.2%) were positive 
for influenza type A antibodies. Out of the positive sera (76), a number of 
45(59.2%) samples were from Khartoum, while the rest 31(40.8%) 
samples were from Omdurman. The variation in the seroprevalence of AI 
in Khartoum and Omdurman may be attributed to the difference between 
the numbers of samples, since only 81 serum samples were from 
Omdurman.  
     The AGID assay is one of the gold standard tests that usually used to 
detect antibodies against type-specific M and NP antigens of type A 
influenza virus. Despite of the AGID test specificity, it has lower 
sensitivity, and commonly takes about 48–72 hours to obtain results 
(WHO, 2005). 
     Salim (1970), used complement fixation test (CFT), which is also used 
to detect antibodies against influenza type A viruses, to estimate the real 
incidence of influenza in the population of the three towns of Khartoum, 
Omdurman and Khartoum North. He found that out of 192 samples, there 
were 123 (64%) with a titer of 1\10 or more. CF titer is presumptive 
evidence of acute infection with influenza A virus. The variation in the 
two results may be due to the fact that Salim`s samples were collected 
from acute ill patients with some or all of influenza symptoms and not 
randomly like ours. 
      The hemagglutination inhibition test was performed, in the present 
work, for sub-typing of AGID positive sera using H5N1 and H7N3 
viruses as antigens .The antibodies to the two avian influenza A subtypes 
were detected in both Khartoum and Omdurman serum samples. The 
results revealed that, 13 out of the 76(17.1%) samples, which were 
positive by AGID, were positive for H5 when HI test was applied. And 
only 5(6.57%) samples were positive when tested by HI test using H7N3 
as antigen. 
     From the 45 serum samples collected in Khartoum, which were 
positive by AGID test, there were only 8 tested positive for H5, and from 
the 31 samples collected from Ummdorman and were positive to type A 
influenza, there were only 5 positive samples to H5. 
     These results confirm the concept that, HI test is unable to detect the 
lower levels of antibody that may be present in sera from H5N1 virus-
infected individuals (Rowe et al., 1999). Rowe and coauthers detected 
H5-specific antibody in only one serum sample, from 16 individuals 
confirmed or suspected to be infected with H5N1 virus, with high 
neutralizing-antibody titers and could not detect the relatively low serum 
antibody titers that developed in many individuals following primary 
infection with avian H5N1 virus.  
     The results that obtained by HI test for H7, are consider low compared 
with those obtained by Meijer et al (2006) who detected antibodies in 
high titers against A H7 virus in human sera (49% of 508 persons 
exposed to poultry and in 64% of 63 persons exposed to A (H7) infected 
persons) using horse erythrocytes instead of chicken RBCs and 2HAU of 
virus suspension. Horse erythrocyte agglutination requires recognition of 
NeuGc_ (2, 3) Gal receptor (Ito et al., 1997), and sera from A (H7) 
infected persons could inhibit this agglutination efficiently. In our HI test, 
we employed whole virus rather than split virus antigen, and other 
researchers have suggested that the HI test is more sensitive when split 
virus antigen is used. Also the choice of the ideal method for treating sera 
to inactivate inhibitors, which depends on the nature of inhibitor present 
and the virus, may increase the sensitivity of the results (Subbarao, 
Kawaoka, Ryan-Poirier, Clements, and   Murphy., 1992).  
   This study was performed for the first time to detect antibodies against 
influenza A viruses in human sera collected from Khartoum state. 
    One of the observations from this study is that, all age groups, in this 
survey, were exposed to infection with influenza A virus and this may be 
attributed to the ability of person to person transmission of human type A 
influenza viruses. In contrast the infection with AI viruses is limited to 
the most socially active groups, those ranged between 20 and 50 years old 
individuals only, due to the need of close contact with infected birds to be 
transmitted.  
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion and Recommendations: 
 
Conclusion: 
The outcome of this study proved the prevalence, of type A influenza in a 
percentage of 34.2% in human in Khartoum state, and revealed that there 
is a remarkable presence of H5 and H7 avian influenza antibodies in 
human sera in Khartoum state population. Also this study indicated that 
AGID test is reliable on to detect antibodies against influenza type A, 
even in case of no apparent clinical signs. 
 
Recommendations:  
1.   Since influenza disease became one of the major human health 
concerns, it is recommended to improve the methods of diagnosis and 
sero-survey of influenza in humans.  
2.  More studies are needed to determine the circulating subtypes of 
influenza A among humans and avian in Sudan.  
3.  Local production of laboratories reagents including antigens and 
antibodies is needed to improve diagnosis. 
 4.  Finally, another survey could be done using split antigens and horse 
RBCs.  
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